From GlobeNewswire.: 2025-03-24 16:05:00

Artiva Biotherapeutics expects initial data for AlloNK® from autoimmune program in H1 2025. Updated clinical data from Phase 1/2 trial with AlloNK + rituximab in NHL to be presented in 2025. Leadership strengthened with autoimmune expertise. Financially strong with $185.4 million in cash, cash equivalents, and investments as of December 31, 2024.

Artiva Biotherapeutics reported a transformative year in 2024, including dosing AlloNK® in patients with autoimmune diseases and a successful IPO. Key leadership was expanded with autoimmune expertise. Initial data for AlloNK® in autoimmune diseases expected in 2025. Updated clinical data from NHL trial to be presented in 2025.

Artiva appointed Dr. Dan Baker to the Board of Directors and key leadership in January 2025. Expecting initial data for AlloNK® in autoimmune diseases in H1 2025. Updated clinical data from Phase 1/2 trial in NHL to be presented in 2025.

Financially, Artiva has $185.4 million in cash, cash equivalents, and investments as of December 31, 2024. Collaboration revenue was zero for 2024. Research and development expenses were $50.3 million for both 2024 and 2023. General and administrative expenses were $17.2 million in 2024.

AlloNK® program expects initial data for autoimmune indications in H1 2025. Ongoing trials include SLE/LN and an investigator-initiated basket trial. Updated clinical data from Phase 1/2 trial in NHL to be presented in 2025. Artiva had $185.4 million in cash, cash equivalents, and investments as of December 31, 2024.



Read more at GlobeNewswire.:: Artiva Biotherapeutics Reports Full Year 2024 Financial